EA015566B1 - Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая - Google Patents

Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая Download PDF

Info

Publication number
EA015566B1
EA015566B1 EA200701594A EA200701594A EA015566B1 EA 015566 B1 EA015566 B1 EA 015566B1 EA 200701594 A EA200701594 A EA 200701594A EA 200701594 A EA200701594 A EA 200701594A EA 015566 B1 EA015566 B1 EA 015566B1
Authority
EA
Eurasian Patent Office
Prior art keywords
use according
dopamine antagonist
day
pharmaceutical composition
compound
Prior art date
Application number
EA200701594A
Other languages
English (en)
Russian (ru)
Other versions
EA200701594A1 (ru
Inventor
Томас Штёр
Original Assignee
ЮСиБи ФАРМА ГМБХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by ЮСиБи ФАРМА ГМБХ filed Critical ЮСиБи ФАРМА ГМБХ
Publication of EA200701594A1 publication Critical patent/EA200701594A1/ru
Publication of EA015566B1 publication Critical patent/EA015566B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA200701594A 2005-01-28 2006-01-27 Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая EA015566B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia
PCT/EP2006/000722 WO2006079547A2 (en) 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia

Publications (2)

Publication Number Publication Date
EA200701594A1 EA200701594A1 (ru) 2008-02-28
EA015566B1 true EA015566B1 (ru) 2011-10-31

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701594A EA015566B1 (ru) 2005-01-28 2006-01-27 Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая

Country Status (12)

Country Link
EP (1) EP1841417A2 (es)
JP (1) JP2008528532A (es)
KR (1) KR20070096058A (es)
AR (1) AR057643A1 (es)
AU (1) AU2006208630B2 (es)
BR (1) BRPI0607043A2 (es)
CA (1) CA2595330A1 (es)
EA (1) EA015566B1 (es)
IL (1) IL183973A0 (es)
MX (1) MX2007009070A (es)
NO (1) NO20074361L (es)
WO (1) WO2006079547A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
MX2019007391A (es) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
AU2018378348A1 (en) 2017-12-05 2020-06-18 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CITROME LESLIE: "Schizophrenia and valproate." PSYCHOPHARMACOLOGY BULLETIN. 2003, vol. 37 Suppl 2, 2003, pages 74-88, XP009035196 ISSN: 0048-5764 cited in the application page 76 page 85 *
FOUNTAIN NATHAN V. ET AL.: "Absence of effect of adjunctive SPM 927 on concomitant AED plasma concentrations in subjects with partial seizures." EPILEPSIA, vol. 44, no. Supplement 9, 2003, page 96, XP009028153 & ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY; BOSTON, MA, USA; DECEMBER 05-10, 2003 ISSN: 0013-9580 abstract *
HORSTMANN ROLF ET AL.: "SPM 927 does not interact with valproic acid and carbamazepine." EPILEPSIA, vol. 44, no. Supplement 9, 2003, page 97, XP009028152 & ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY; BOSTON, MA, USA; DECEMBER 05-10, 2003 ISSN: 0013-9580 abstract *

Also Published As

Publication number Publication date
BRPI0607043A2 (pt) 2009-08-04
AU2006208630A1 (en) 2006-08-03
WO2006079547A3 (en) 2006-09-21
NO20074361L (no) 2007-10-26
JP2008528532A (ja) 2008-07-31
CA2595330A1 (en) 2006-08-03
WO2006079547A2 (en) 2006-08-03
AU2006208630B2 (en) 2011-09-29
EA200701594A1 (ru) 2008-02-28
AR057643A1 (es) 2007-12-12
KR20070096058A (ko) 2007-10-01
EP1841417A2 (en) 2007-10-10
IL183973A0 (en) 2008-12-29
MX2007009070A (es) 2007-09-12

Similar Documents

Publication Publication Date Title
EA015566B1 (ru) Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
US11529342B2 (en) Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
AU2003227516B2 (en) A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US20060276412A1 (en) Methods and compositions for managing psychotic disorders
JP2007517901A (ja) 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
WO2009018368A1 (en) Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
CA2530381C (fr) Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes
WO2005120523A1 (en) Methods and compositions for treating mood disorder
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MXPA02004410A (es) Tratamiento de combinacion para la ansiedad y la depresion.
EP1576985A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
DK2694065T3 (en) COMPOSITION FOR TREATMENT OF DISORDER WITH SEXUAL SEXUAL LISTENING
MXPA02003452A (es) Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica.
AU2007312209A1 (en) Composition comprising an NK-1 receptor antagonist and an SSRI for the treatment of tinnitus and hearing loss
CA2461248C (en) Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP1545546B1 (en) Treatment of dyskinesia with 2,3-benzodiazepines
CA2865845A1 (en) An iloperidone metabolite for use in the treatment of psychiatric disorders
EP1326616A1 (en) New use of quetiapine
US20080139573A1 (en) Treatment of resistant Schizophrenia and other CNS disorders
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
WO2018002937A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
JP2007522175A (ja) 社会恐怖症の治療用の２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル−ベンジル）−２ｓ−フェニル−ピペリジン−３ｓ−イル）アミン
WO2012072665A1 (en) Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU